LXEO logo

LXEO Lexeo Therapeutics Inc.

$3.22
$0.09
(2.72%)
Pre-Market
58

Bullish Sentiment

How do you feel about LXEO?

Loading...
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich AtaxiaPR NewswireNEW YORK, Sept. 23, 2026 NEW YORK, Sept. 23, 2026...
PR Newswire
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.read more...
Benzinga
Lexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich Ataxia
(RTTNews) - Lexeo Therapeutics, Inc. (LXEO), a clinical stage company, announced Tuesday a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire private clinical stage company Mantle Therapeut...
Nasdaq News: Markets
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple...
Yahoo! Finance: News
Why Is Lexeo Therapeutics Stock Gaining Monday?
Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment set to begin in June 2026.read more...
Benzinga
Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday
Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-lexeo-therapeutics-inc-stock...
MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Brokerages
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one...
MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen cut Lexeo Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Should You Buy?
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Here's What Happened...
MarketBeat